In this 3-part podcast series, the International Federation on Ageing (IFA) aims to raise awareness of hMPV. The series will feature scientists, clinicians and the voices of older people and groups representing those most at risk of serious disease.

New respiratory syncytial virus (RSV) vaccines have been approved in the USA for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 years and older.

Frequency, phenotype and T-cell receptor (TCR) composition of influenza-specific CD8+ T-cells directed at the prominent A2/M158 influenza epitope change across the human lifespan.

The VITAL project published an educational platform as well as a toolbox to boost vaccination uptake amongst older people.

In Denmark, people aged 65 and older were offered free seasonal influenza vaccination from 1 October to 31 December 2024.

Older adults, especially those over 65 years of age, face increased risks of immune senescence, chronic comorbidities, and decreased vaccine efficacy.

This Review provides an overview of RSV vaccines highlighting different target populations, antigens, and trial results. As RSV vaccines have not yet reached low-income and middle-income countries, next steps are outlined to minimise the delay.

ESWI addresses common questions and misconceptions amongst the general public regarding influenza, COVID-19 and RSV. These responses, elaborated by ESWI Board Members and coalition partners, aim to increase public awareness and prevent misinformation.